Navigation Links
CalciMedica Initiates Phase 1 Clinical Studies for CRAC Channel Inhibitor
Date:1/6/2017

LA JOLLA, Calif., Jan. 6, 2017 /PRNewswire/ -- Privately-held CalciMedica, Inc., announced that it started Phase 1 safety studies in healthy volunteers of a novel calcium release-activated calcium (CRAC) channel inhibitor, CM4620, intended to treat acute pancreatitis.

Acute pancreatitis, sudden painful inflammation of the pancreas, is typically a mild disorder, but can be very serious.  In severe cases it can lead to organ failure and sepsis, where extended hospital stays, time in the ICU and substantial morbidity and even mortality are seen. Acute pancreatitis has many different causes, ranging from alcohol and gall stones, which are responsible for the majority of cases, to drug reactions, viral infections or local cancers; there are also hereditary forms.  At this time there are no disease-modifying therapies available; patients receive supportive care, including fluids and pain medication.

Michael Dunn, President of CalciMedica, said, "We are very excited that CM4620 has advanced to human studies.  Acute pancreatitis is a disease with significant unmet medical need, especially its more severe form.  Our preclinical work and that of others strongly indicates that excess calcium in pancreatic cells is a key player in this disease.  We believe that CM4620 can help to modify the disease process and benefit patients, and hope to progress from these safety studies to testing in patients by the end of this year."

About CRAC channels and Orai

CRAC channels, comprising Orai and regulatory STIM proteins, function to maintain proper levels of calcium in most non-excitable cells.  In immune cells, particularly T cells, calcium is an important intracellular signaling molecule that controls cytokine production and the immune response.  In T cells CRAC channels are the primary means by which intracellular calcium levels are modulated.  In addition, aberrant activation of CRAC channels in pancreatic acinar cells is thought to play a key role in the pathobiology of acute pancreatitis.

About CalciMedica, Inc.

CalciMedica is the leading biopharmaceutical company focused on CRAC channel drug discovery and development, seeking novel drugs for the treatment of acute or chronic diseases in which inflammation plays a role. For example, CRAC channels control calcium entry that is essential for the adaptive immune response, and this pathway has been clinically validated as an important drug target in humans through the use of calcineurin inhibitors that act downstream from CRAC channels. For more information, please visit the company website at www.calcimedica.com.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/calcimedica-initiates-phase-1-clinical-studies-for-crac-channel-inhibitor-300386948.html


'/>"/>
SOURCE CalciMedica, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology news :

1. Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform
2. China National Genebank initiates collaboration to sequence transcriptomes of 1,000 fish species
3. Alios BioPharma initiates Phase 1 clinical trial for respiratory syncytial virus infection
4. Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism
5. NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer
6. Rolapitant reduces nausea and vomiting in Phase III trial
7. NIH funds next phase of Tissue Chip for Drug Screening program
8. Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN
9. New simple setup for X-ray phase contrast
10. More than just a hill of beans: Phaseolus genome lends insights into nitrogen fixation
11. ASU embarks on $9 million next phase of an effort to assess an absorbed radiation dose
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2018)... ... December 04, 2018 , ... ... oligo synthesizer, the Dr. Oligo 192c, built on Biolytic’s Molecule Synthesis Platform. ... have allowed them to become the world’s fastest in oligonucleotide synthesis, the 192c ...
(Date:11/29/2018)... Pa. (PRWEB) , ... November 29, 2018 , ... ... investment in Semba Biosciences with the intention of acquiring full ownership. The transaction ... Participation Agreement was executed on November 14, 2018. “We are extremely pleased to ...
(Date:11/27/2018)... ... 26, 2018 , ... PulseEd™ uses researched technology, published in the Journal ... blood flow to the penis. Regular and unimpeded blood flow to the blood vessels ... erectile function. The recorded results of SWT (sound wave therapy), indicated that almost 80% ...
Breaking Biology News(10 mins):
(Date:11/29/2018)... ... 2018 , ... RAGS, today announced the closing of a $1.5 million Second ... existing investor and board member Jeremy Andrus, CEO of Traeger Grills, as well as ... enable the company to accelerate its growth and expand the product line. RAGS has ...
(Date:11/27/2018)... ... 27, 2018 , ... New patients in need of a dental crown ... with or without a referral. Dr. Myers has many years of experience improving patient ... bridges and custom crowns. , As a dedicated cosmetic dentist , Dr. ...
(Date:11/20/2018)... VANCOUVER, British Columbia (PRWEB) , ... November 19, ... ... Repositories (ISBER) is pleased to announce the release of the Chinese translation of ... released in January 2018, is a practice-changing publication aimed at advancing the science ...
(Date:11/20/2018)... ... ... Each year Forbes receives thousands of nominations for candidates wishing to be ... under 30 years of age. The Forbes 30 Under 30 list showcases the top ... Capital and Science. , In 2017, Visikol CEO Dr. Michael Johnson was named ...
Breaking Biology Technology: